Nivolumab in combination with azacitidine in patients with relapsed acute myeloid leukemia (AML)
Naval G. Daver
The influence of the European Research Initiative on CLL (ERIC)
Recognizing clonal hematopoiesis – diagnostic challenges and clinical relevance
Key questions to be discussed at iwCLL 2017: cancer genetics, immunology and categorizing patients
Are IDH mutations good minimal residual disease (MRD) markers in acute myeloid leukemia (AML)?